Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection

[1]  G. Fröschl,et al.  Serotype influences on dengue severity: a cross-sectional study on 485 confirmed dengue cases in Vitória, Brazil , 2016, BMC Infectious Diseases.

[2]  C. W. Ong.  Zika virus: an emerging infectious threat , 2016, Internal medicine journal.

[3]  R. Borchardt.  Zika virus: A rapidly emerging infectious disease. , 2016, JAAPA : official journal of the American Academy of Physician Assistants.

[4]  E. Zerhouni,et al.  Once and future epidemics: Zika virus emerging , 2016, Science Translational Medicine.

[5]  Diana Montes-Grajales,et al.  Discovery of antiviral molecules for dengue: In silico search and biological evaluation. , 2016, European journal of medicinal chemistry.

[6]  S. S. Sohrab,et al.  Tackling dengue fever: Current status and challenges , 2015, Virology Journal.

[7]  Xing-quan Zhang.  Direct anti-HCV agents , 2015, Acta pharmaceutica Sinica. B.

[8]  J. D. Beckham,et al.  West Nile Virus Encephalitis 16 Years Later , 2015, Brain pathology.

[9]  A. Schlachterman,et al.  Hepatitis C: Treatment of difficult to treat patients. , 2015, World journal of hepatology.

[10]  T. Ishikawa,et al.  Potential chemotherapeutic targets for Japanese encephalitis: current status of antiviral drug development and future challenges , 2015, Expert opinion on therapeutic targets.

[11]  Dahai Luo,et al.  The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development. , 2015, Antiviral research.

[12]  Dennis A Bente,et al.  Yellow fever virus: genetic and phenotypic diversity and implications for detection, prevention and therapy. , 2015, Antiviral research.

[13]  Ezequiel Panepucci,et al.  Fast native-SAD phasing for routine macromolecular structure determination , 2014, Nature Methods.

[14]  C. Schiffer,et al.  Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease , 2014, ACS chemical biology.

[15]  F. Morisco,et al.  Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection , 2014, Therapeutics and clinical risk management.

[16]  A. Poulsen,et al.  Drug design for flavivirus proteases: what are we missing? , 2014, Current pharmaceutical design.

[17]  Bin Wang,et al.  Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. , 2014, Journal of medicinal chemistry.

[18]  A. Good,et al.  Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. , 2014, Journal of medicinal chemistry.

[19]  Hongmin Li,et al.  The flavivirus protease as a target for drug discovery , 2013, Virologica Sinica.

[20]  David Beer,et al.  Ten years of dengue drug discovery: progress and prospects. , 2013, Antiviral research.

[21]  Kai-Cheng Hsu,et al.  Pathway-based Screening Strategy for Multitarget Inhibitors of Diverse Proteins in Metabolic Pathways , 2013, PLoS Comput. Biol..

[22]  A. Poulsen,et al.  Novel agmatine dipeptide inhibitors against the West Nile virus NS2B/NS3 protease: a P3 and N-cap optimization study. , 2013, European journal of medicinal chemistry.

[23]  John S. Brownstein,et al.  The global distribution and burden of dengue , 2013, Nature.

[24]  R. Hilgenfeld,et al.  Development and Characterization of New Peptidomimetic Inhibitors of the West Nile Virus NS2B–NS3 Protease , 2013, ChemMedChem.

[25]  G. Silva,et al.  Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors , 2013, Memorias do Instituto Oswaldo Cruz.

[26]  I. Jacobson,et al.  Telaprevir for chronic hepatitis C virus infection. , 2013, Clinics in liver disease.

[27]  Bo Zhang,et al.  Mutagenesis of D80-82 and G83 residues in West Nile Virus NS2B: Effects on NS2B-NS3 activity and viral replication , 2013, Virologica Sinica.

[28]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[29]  A. Ascione.  Boceprevir in chronic hepatitis C infection: a perspective review , 2012, Therapeutic advances in chronic disease.

[30]  R. Talwani,et al.  Current status of treatment for chronic hepatitis C virus infection. , 2012, Drugs of today.

[31]  David W Smith,et al.  Murray Valley encephalitis: a review of clinical features, diagnosis and treatment , 2012, The Medical journal of Australia.

[32]  Kai-Cheng Hsu,et al.  Core Site-Moiety Maps Reveal Inhibitors and Binding Mechanisms of Orthologous Proteins by Screening Compound Libraries , 2012, PloS one.

[33]  P. Shi,et al.  Ligand-Bound Structures of the Dengue Virus Protease Reveal the Active Conformation , 2011, Journal of Virology.

[34]  S. Vasudevan,et al.  Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease. , 2011, Antiviral research.

[35]  R. Bartenschlager,et al.  Synthesis and biological evaluation of α-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture. , 2011, Bioorganic & medicinal chemistry.

[36]  Kai-Cheng Hsu,et al.  iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis , 2011, BMC Bioinformatics.

[37]  Niranjan Kissoon,et al.  Dengue hemorrhagic fever and shock syndromes* , 2011, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[38]  C. Schiffer,et al.  Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding , 2010, Proceedings of the National Academy of Sciences.

[39]  A. Strongin,et al.  Structural and functional parameters of the flaviviral protease: a promising antiviral drug target. , 2010, Future virology.

[40]  G. Katzenmeier,et al.  Structure-guided mutagenesis of active site residues in the dengue virus two-component protease NS2B-NS3 , 2010, Journal of Biomedical Science.

[41]  David I. Stuart,et al.  Structure and functionality in flavivirus NS-proteins: Perspectives for drug design , 2010, Antiviral research.

[42]  Kai-Cheng Hsu,et al.  SiMMap: a web server for inferring site-moiety map to recognize interaction preferences between protein pockets and compound moieties , 2010, Nucleic Acids Res..

[43]  Tal Pupko,et al.  ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids , 2010, Nucleic Acids Res..

[44]  B. Geiss,et al.  Focus on flaviviruses: current and future drug targets. , 2009, Future medicinal chemistry.

[45]  Yuan-Ping Pang,et al.  Structure-based discovery of dengue virus protease inhibitors. , 2009, Antiviral research.

[46]  D. Gubler,et al.  Dengue/dengue haemorrhagic fever: history and current status. , 2008, Novartis Foundation symposium.

[47]  D. Fairlie,et al.  Mutagenesis of the West Nile virus NS2B cofactor domain reveals two regions essential for protease activity. , 2008, The Journal of general virology.

[48]  Zhuyan Guo,et al.  Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. , 2007, Journal of medicinal chemistry.

[49]  Martin J. Stoermer,et al.  Insights to Substrate Binding and Processing by West Nile Virus NS3 Protease through Combined Modeling, Protease Mutagenesis, and Kinetic Studies* , 2006, Journal of Biological Chemistry.

[50]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[51]  S. Vasudevan,et al.  Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors. , 2006, Journal of medicinal chemistry.

[52]  Weiying Yang,et al.  Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: , 2006, Journal of medicinal chemistry.

[53]  C. Rice,et al.  Structure of the catalytic domain of the hepatitis C virus NS2-3 protease , 2006, Nature.

[54]  X. Tong,et al.  Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. , 2006, Antiviral research.

[55]  Zheng Yin,et al.  Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus , 2006, Nature Structural &Molecular Biology.

[56]  B. Picard,et al.  Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients , 2005, Journal of Medical Virology.

[57]  A. Molla,et al.  Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro , 2004, Antimicrobial Agents and Chemotherapy.

[58]  Jinn-Moon Yang,et al.  GEMDOCK: A generic evolutionary method for molecular docking , 2004, Proteins.

[59]  L. Pacini,et al.  In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor , 2003, Journal of Virology.

[60]  B. Malcolm,et al.  Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity , 2001, Proteins.

[61]  P E Bourne,et al.  Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. , 1998, Protein engineering.

[62]  R. Cortese,et al.  Product inhibition of the hepatitis C virus NS3 protease. , 1998, Biochemistry.

[63]  B. Falgout,et al.  Mutagenesis of the NS3 Protease of Dengue Virus Type 2 , 1998, Journal of Virology.

[64]  M. Sato,et al.  Proteolytic activity of NS3 serine proteinase of hepatitis C virus efficiently expressed in Escherichia coli. , 1995, Hepatology.

[65]  C. Rice,et al.  Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites , 1993, Journal of virology.

[66]  P. Ferenci.  Viral hepatitis: Cure of chronic hepatitis C—required length of follow-up? , 2015, Nature Reviews Gastroenterology &Hepatology.

[67]  A. Sampath,et al.  Molecular targets for flavivirus drug discovery. , 2009, Antiviral research.

[68]  S. Vasudevan,et al.  Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[69]  F. G. Njoroge,et al.  Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity. , 2006, Bioorganic & medicinal chemistry letters.